Is it at risk for melanoma?

DermTech it
and KNOW

tooltip text

Negative Predictive Value is the proportion of cases with negative test results that are true negatives

Sensitivity is the test's ability to designate an individual with disease as positive.

Enhance early melanoma detection with the DermTech Melanoma Test

tooltip text

Negative Predictive Value is the proportion of cases with negative test results that are true negatives

Sensitivity is the test's ability to designate an individual with disease as positive.

The DermTech Melanoma Test is a non-invasive genomic test utilizing DermTech Smart Stickers™ to assess suspicious melanocytic lesions meeting one or more of the ABCDE criteria. It detects genomic markers associated with melanoma to identify high-risk lesions at their earliest stages.1,a

The test provides objective, actionable, easy-to-interpret results that distinguish benign from high-risk lesions.1,4

Recommended use of the DermTech Melanoma Test

Indicated for use on melanocytic lesions having one or more ABCDE criteria (Asymmetry, Border, Color, Diameter, Evolving)

Additional considerations for use may include5:

  • Difficult-to-biopsy areas
  • Cosmetically sensitive areas
  • Patients who are not good biopsy candidates

Detecting melanoma early begins in the genome6

Melanoma development is driven by gene mutations and atypical cell proliferation.6

How to use the DermTech Melanoma Test

Watch our video for details on using the DermTech Smart Stickers™ to collect skin cells from a suspicious lesion. It takes less than 5 minutes per lesion and can be performed by medical staff or at home under supervision.

Broad insurance coverage

The DermTech Melanoma Test is covered by several major insurance providers, and with $0 out-of-pocket costs for Medicare.a

Friendly billing assistance

Our Patient Concierge Team representatives are ready to help patients with insurance coverage questions and financial assistance for those who qualify — because we believe hardships should not stand in the way of patient care. Just call 858-291-7500.

Questions?

If you would like more information or to get started with the DermTech Melanoma Test, please contact us.

Medicare patients have $0 out-of-pocket costsa

Most patients pay less than

$75

per DermTech Melanoma Testb

Broad insurance coverage

Medicare patients have $0 out-of-pocket costsa

Most patients pay less than

$75

per DermTech Melanoma Testb

The DermTech Melanoma Test is covered by several major insurance providers, and with $0 out-of-pocket costs for Medicare.a

Friendly billing assistance

Our Patient Concierge Team representatives are ready to help patients with insurance coverage questions and financial assistance for those who qualify — because we believe hardships should not stand in the way of patient care. Just call 858-291-7500.

Questions?

If you would like more information or to get started with the DermTech Melanoma Test, please contact us.

Let’s help end melanoma deaths.
Partner with DermTech.

Together, we can help stop melanoma by:

DermTech is supporting the mission to help end melanoma deaths by educating patients on the importance of skin exams.

aThe DermTech Melanoma Test is comprised of 2 assays:

  1. The Pigmented Lesion Assay (PLA) detects 2 RNA biomarkers: LINC00518 and PRAME.
  2. The TERT Add-On Assay detects DNA TERT promoter mutations and is only run following PLA testing when ordered and if sufficient genomic material is available. The TERT Add-On Assay does not yet have
    Medicare coverage.

b87% of patients pay less than $75. Data through August 24, 2021.

*The DermTech Melanoma Test is not intended to be used as a screening test. Please review the test requisition form for additional intended use criteria for ordering the DermTech Melanoma Test here. View test requisition form.

References: 1. Gerami P, et al. J Am Acad Dermatol. 2017;76(1):114-120. 2. Jackson S, et al. SKIN J Cutan Med. 2020;4(2):105-110. 3. Skelsey M, et al. SKIN J Cutan Med. 2021;5(5):512-523. 4. Ferris L, et al. Dermatol Online J. 2019;25(5):2. 5. Brouha B, et al. J Drugs Dermatol. 2020;19(3):257-262. 6. Elder D. Pathology. 2016;48(2):147-154.